Abstract Number: 1735 • 2019 ACR/ARP Annual Meeting
Clinical Variables Influencing Prednisone Dosing Towards the Development of Corticosteroid Treatment Algorithms in Pediatric Proliferative Lupus Nephritis
Background/Purpose: Corticosteroids (CS) are the mainstay of childhood-onset systemic lupus erythematosus (cSLE) and proliferative lupus nephritis (LN) therapy. However, there are no widely accepted CS…Abstract Number: 2024 • 2019 ACR/ARP Annual Meeting
Genetics of Longitudinal Kidney Function in Children and Adults with Systemic Lupus Erythematosus
Background/Purpose: Genetics influences kidney function (estimated glomerular filtration rate (eGFR)), systemic lupus erythematosus (SLE) and lupus nephritis (LN) risk. Genome-wide association studies (GWAS) have identified…Abstract Number: 2284 • 2019 ACR/ARP Annual Meeting
The Titer of Anti-Double Stranded DNA Antibody Could Affect the Apgar Score of Newborns, Which Is Considered as the Predictive Clinical Index for Neurological or Physical Development
Background/Purpose: Recently, the progression of treatment strategy enabled many systemic lupus erythematosus (SLE) women to become mothers. On the other hand, some reports have revealed…Abstract Number: 2534 • 2019 ACR/ARP Annual Meeting
Vitamin D Reduces Cardiovascular Risk Factors in SLE
Background/Purpose: Vitamin D has effects on the cardiovascular system, including decreased renin-angiotensin, decreased insulin resistance, increased vascular relaxation and decreased vascular smooth muscle cell proliferation,…Abstract Number: 2734 • 2019 ACR/ARP Annual Meeting
Signaling Lymphocytic Activation Molecule Family (SLAMF) Receptors Deregulation Is Implicated in the Altered Function of NK Cells in Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease characterized by quantitative and qualitative deficiencies of immune cells. Natural killer (NK) cells are innate…Abstract Number: 2864 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus: An Across-Trial Comparison with the Adult Belimumab Studies
Background/Purpose: Belimumab (BEL) is the first treatment approved for children with systemic lupus erythematosus (SLE) from 5 years of age and older.1 This approval was…Abstract Number: 95 • 2019 ACR/ARP Annual Meeting
IL-21-mediated Suppression of STAT5 Phosphorylation Underlies Treg Depletion and Dysfunction in SLE
Background/Purpose: IL-21 activates mechanistic target of rapamycin (mTOR) complexes 1 and 2 which in turn block regulatory T (Treg)-cell differentiation and function in patients with…Abstract Number: 674 • 2019 ACR/ARP Annual Meeting
Affordability Concerns Prevalent Among Patients with Systemic Lupus Erythematosus (SLE)
Background/Purpose: Among rheumatologic conditions, SLE is associated with very high healthcare and out of pocket costs. Little is known about patients’ concerns regarding costs of…Abstract Number: 896 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Use and Cardiovascular Events Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Background/Purpose: Hydroxychloroquine (HCQ) is near-universally recommended for patients with SLE and is often used in the treatment of RA. Use of HCQ has been associated…Abstract Number: 1091 • 2019 ACR/ARP Annual Meeting
Risk of Preterm Birth by Timing of Lupus Diagnosis Among Women in the Georgia Lupus Registry
Background/Purpose: Women with systemic lupus erythematosus (SLE) are at a greater risk of having a preterm birth than the general population. Most studies examine preterm…Abstract Number: 1559 • 2019 ACR/ARP Annual Meeting
Routine Clinical Pathology Measurements Are Predictive of the Risk of Organ Damage Accrual in SLE
Background/Purpose: Prevention of permanent organ damage, a major predictor of morbidity and mortality, is a key goal in the treatment of SLE. Physician-measured disease activity…Abstract Number: 1603 • 2019 ACR/ARP Annual Meeting
Stroke Clusters in SLE by Lupus Autoantibodies
Background/Purpose: Stroke is the most common arterial thrombotic event in SLE. It is known to be associated with antiphospholipid antibodies, but clinicians have additional concern…Abstract Number: 1761 • 2019 ACR/ARP Annual Meeting
The Prospective Open Label Preventive Approach to Congenital Heart Block with Hydroxychloroquine (PATCH) Study Demonstrates a Reduction in the Recurrence Rate of Advanced Block
Background/Purpose: Based on encouraging bench to bedside results including experimental evidence supporting Toll-like receptor signaling in the pathogenesis of CHB, a case control study demonstrating…Abstract Number: 2025 • 2019 ACR/ARP Annual Meeting
Ancestry Influences the Gene Expression Profile in Systemic Lupus Erythematosus and Contributes to Transcriptomic Heterogeneity in Lupus Patients
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease with both sex and ancestral bias. Gene expression analysis has revealed complex heterogeneity between SLE…Abstract Number: 2285 • 2019 ACR/ARP Annual Meeting
Higher Than Expected Rates of Adverse Pregnancy Outcomes in Patients with Systemic Lupus Erythematosus from Three Tertiary Care Centers
Background/Purpose: Prospective cohort studies of pregnancies managed by experts demonstrate that up to 30% of systemic lupus erythematosus (SLE) pregnancies result in preterm birth. We…
- « Previous Page
- 1
- …
- 134
- 135
- 136
- 137
- 138
- …
- 150
- Next Page »